Timothy J Hatlen, M.D.
Timothy Hatlen is an Assistant Professor of Health Sciences at the David Geffen School of Medicine at UCLA, Program Director of the Adult Infectious Diseases Fellowship at Harbor-UCLA Medical Center, and a practicing Infectious Diseases and HIV specialist providing consultative and primary care to patients at Harbor-UCLA Medical Center and Long Beach Community Health Center.
His current research interests are in HIV related therapeutics, linkage to care, and improvement in comorbidities in people living with HIV. He is extensively involved in outpatient and inpatient COVID-19 research and Long COVID. He is the clinical director for the Hepatitis C clinic at Harbor-UCLA Medical Center with research interests in novel therapeutics and improvements to local elimination implementation strategies.
Areas of Expertise
- HIV- including prevention, treatment, complications of HIV, implementation studies for improvement in access to care, and improving quality of life of co-morbid conditions
- Hepatitis C
- COVID-19 – clinical research involving outpatients, inpatients, and those impacted with Long COVID
- General Infectious Diseases
Education
- B.A., University of Washington, Seattle, WA
- M.D., University of Washington School of Medicine, Seattle, WA
- Internship and Residency, Internal Medicine, Internal Medicine Residency of Spokane, Spokane, WA
- Fellowship, Infectious Diseases, Harbor-UCLA Medical Center, Torrance, CA
Publications
- “Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial”, Lancet Respir Med., [Epub 8 July 2022]. (PMID: 35817072)
- Fetters, K.B., Judge, S.P., Daar, E.S., Hatlen, T.J. Burden of Hyperglycemia in Patients Receiving Corticosteroids for Severe COVID-19. Mayo Clinic Proceedings: Innovations, Quality & Outcomes. 2022 Oct; 6(5): 484–487. PMID: 35966031
- Jensen TO, Grandits GA, Jain MK, Murray TA, Grund B, Shaw-Saliba K, Matthay MA, Abassi M, Ardelt M, Baker JV, Chen P, Dewar RL, Goodman AL, Hatlen TJ, Highbarger HC, Holodniy M, Lallemand P, Laverdure S, Leshnower BG, Looney D, Moschopoulos CD, Mugerwa H, Murray DD, Mylonakis E, Nagy-Agren S, Rehman MT, Rupert A, Stevens RA, Turville S, Weintrob A, Wick K, Lundgren J, Ko ER; ACTIV-3/TICO Study Group. Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19. J Infect Dis. 2023 Nov 9:jiad446. doi: 10.1093/infdis/jiad446. PMID: 37948759.
- Murphy RA, Bedesi PH, Perumal N, Gosnell BI, Hatlen TJ, Jaysingh Brijkumar J. Dolutegravir resistance in African programmatic settings among patients with failure of dolutegravir-based ART. OFID. 2024 (DOI: 10.1093/ofid/ofae321)
A list of publications can be found here
© 2024 Lundquist. All rights reserved